[go: up one dir, main page]

WO2012028524A3 - Procédé de production d'une particule lipidique, particule lipidique elle-même et son utilisation - Google Patents

Procédé de production d'une particule lipidique, particule lipidique elle-même et son utilisation Download PDF

Info

Publication number
WO2012028524A3
WO2012028524A3 PCT/EP2011/064600 EP2011064600W WO2012028524A3 WO 2012028524 A3 WO2012028524 A3 WO 2012028524A3 EP 2011064600 W EP2011064600 W EP 2011064600W WO 2012028524 A3 WO2012028524 A3 WO 2012028524A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid particle
producing
apolipoprotein
tetranectin
itself
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/064600
Other languages
English (en)
Other versions
WO2012028524A2 (fr
Inventor
Martin Bader
Monika Baehner
Adelbert Grossmann
Silke Mohl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN2011800386711A priority Critical patent/CN103068368A/zh
Priority to CA2807433A priority patent/CA2807433A1/fr
Priority to JP2013526413A priority patent/JP2013544488A/ja
Priority to RU2013111678/15A priority patent/RU2013111678A/ru
Priority to EP11749404.7A priority patent/EP2611419A2/fr
Priority to MX2013001541A priority patent/MX2013001541A/es
Priority to KR1020137005032A priority patent/KR20130047749A/ko
Priority to BR112013004397A priority patent/BR112013004397A2/pt
Publication of WO2012028524A2 publication Critical patent/WO2012028524A2/fr
Publication of WO2012028524A3 publication Critical patent/WO2012028524A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé de production d'une particule lipidique, ce procédé comprenant les étapes suivantes consistant à : i) produire une première solution comprenant une apolipoprotéine dénaturée; ii) ajouter la première solution à une deuxième solution comprenant au moins deux lipides et un détergent, mais pas d'apolipoprotéine, et iii) retirer le détergent de la solution obtenue à l'étape ii) et produire ainsi une particule lipidique.
PCT/EP2011/064600 2010-08-30 2011-08-25 Procédé de production d'une particule lipidique, particule lipidique elle-même et son utilisation Ceased WO2012028524A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN2011800386711A CN103068368A (zh) 2010-08-30 2011-08-25 产生四连蛋白-载脂蛋白a-i脂质颗粒的方法，脂质颗粒本身及其应用
CA2807433A CA2807433A1 (fr) 2010-08-30 2011-08-25 Procede de production d'une particule lipidique, particule lipidique elle-meme et son utilisation
JP2013526413A JP2013544488A (ja) 2010-08-30 2011-08-25 テトラネクチン−アポリポタンパク質ａ−ｉ脂質粒子を産生するための方法、脂質粒子自体、及びその使用
RU2013111678/15A RU2013111678A (ru) 2010-08-30 2011-08-25 Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение
EP11749404.7A EP2611419A2 (fr) 2010-08-30 2011-08-25 Procédé de production d'une particule lipidique de la teranectine-apolipoprotéine a-1, particule lipidique elle-même et son utilisation
MX2013001541A MX2013001541A (es) 2010-08-30 2011-08-25 Metodo para producir una particula lipidica de tetranectina-apolipoproteina a-1, la particula lipidica misma y su uso.
KR1020137005032A KR20130047749A (ko) 2010-08-30 2011-08-25 테트라넥틴-아포지단백질 a-i 지질 입자의 제조 방법, 지질 입자 및 이의 용도
BR112013004397A BR112013004397A2 (pt) 2010-08-30 2011-08-25 método para produzir uma partícula de lipídio, a partícula de lipídio em si e seu uso

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10008995.2 2010-08-30
EP10008995 2010-08-30

Publications (2)

Publication Number Publication Date
WO2012028524A2 WO2012028524A2 (fr) 2012-03-08
WO2012028524A3 true WO2012028524A3 (fr) 2012-11-15

Family

ID=44532851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/064600 Ceased WO2012028524A2 (fr) 2010-08-30 2011-08-25 Procédé de production d'une particule lipidique, particule lipidique elle-même et son utilisation

Country Status (9)

Country Link
EP (1) EP2611419A2 (fr)
JP (1) JP2013544488A (fr)
KR (1) KR20130047749A (fr)
CN (1) CN103068368A (fr)
BR (1) BR112013004397A2 (fr)
CA (1) CA2807433A1 (fr)
MX (1) MX2013001541A (fr)
RU (1) RU2013111678A (fr)
WO (1) WO2012028524A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508664A (ja) 2012-02-29 2015-03-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ カラムでの酵素的切断
CN103408669B (zh) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白，及其制备方法和用途
MX2020006800A (es) 2017-12-28 2020-09-03 Takeda Pharmaceuticals Co Lipidos cationicos.
CN111527204B (zh) 2017-12-28 2023-09-01 国立大学法人京都大学 靶基因改造用组合物
DE202019003092U1 (de) * 2019-07-24 2020-01-17 Ruth-Maria Korth Test zur Bestimmung von Proteophospholipiden und FIDA-Formeln zur Bestimmung von Schutzfaktoren , die mit Substraten auszugleichen sind
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用
CN116396358B (zh) * 2023-06-08 2023-08-29 时夕(广州)生物科技有限公司 一种骨靶向纳米脂质颗粒的制备及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608347A (en) * 1982-04-15 1986-08-26 Bernstam Victor A Compositions, uses and methods creating reverse micelles for the clarification of biological fluids to obtain undistorted assay of analytes following clarification
US5928644A (en) * 1990-09-17 1999-07-27 Biotech Australia Pty Limited T-cell epitopes
WO2005065708A2 (fr) * 2003-12-30 2005-07-21 Wyeth Formulations de proteines hydrophobes dans une composition immunogenique a tolerabilite amelioree
WO2006069371A1 (fr) * 2004-12-22 2006-06-29 Baylor College Of Medicine Methode de lipidation plasmatique destinee a prevenir, a inhiber et/ou a inverser l'atherosclerose
FR2915490A1 (fr) * 2007-04-26 2008-10-31 Univ Joseph Fourier Etablissem Formation de proteoliposomes contenant des proteines membranaires a l'aide d'un systeme de synthese proteique acellulaire
WO2009097587A2 (fr) * 2008-01-30 2009-08-06 The Rockefeller University Bicouches liées nanométriques, procédés d'utilisation et production

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE500941C2 (sv) 1989-08-16 1994-10-03 Algy Persson Förfarande och apparat för snittning av ett preparat
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
EP0972838B1 (fr) 1998-07-15 2004-09-15 Roche Diagnostics GmbH Système de sélection par complémentation d' une auxotrophie en absence d'antibiotique chez E. coli
US6291245B1 (en) 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
AU2001253620A1 (en) 2000-04-14 2001-10-30 Nuvelo, Inc. Materials and methods relating to lipid metabolism
WO2002038609A2 (fr) * 2000-11-10 2002-05-16 Proteopharma Aps Analogues d'apolipoproteine
EP1382614A1 (fr) * 2002-07-15 2004-01-21 Bayer HealthCare AG Procédé de purification de l'interleukine-4 et ses muteines
CA2443365C (fr) 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methodes de production par recombinaison de peptides antifusiogenes
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
US20060019870A1 (en) 2004-01-28 2006-01-26 O'donnell Francis E Jr Apoprotein cochleate compositions
WO2006125304A1 (fr) 2005-05-25 2006-11-30 Liponex, Inc. Compositions pharmaceutiques pour traiter ou prevenir une maladie coronarienne
US8163699B2 (en) 2006-06-01 2012-04-24 Montreal Heart Institute Method for the treatment of valvular disease
CN101889022A (zh) * 2007-10-08 2010-11-17 阿纳福公司 三聚IL-1Ra
MX2010011680A (es) 2008-04-25 2011-05-03 Univ Northwestern Nanoestructuras adecuadas para secuestrar colesterol y otras moleculas.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608347A (en) * 1982-04-15 1986-08-26 Bernstam Victor A Compositions, uses and methods creating reverse micelles for the clarification of biological fluids to obtain undistorted assay of analytes following clarification
US5928644A (en) * 1990-09-17 1999-07-27 Biotech Australia Pty Limited T-cell epitopes
WO2005065708A2 (fr) * 2003-12-30 2005-07-21 Wyeth Formulations de proteines hydrophobes dans une composition immunogenique a tolerabilite amelioree
WO2006069371A1 (fr) * 2004-12-22 2006-06-29 Baylor College Of Medicine Methode de lipidation plasmatique destinee a prevenir, a inhiber et/ou a inverser l'atherosclerose
FR2915490A1 (fr) * 2007-04-26 2008-10-31 Univ Joseph Fourier Etablissem Formation de proteoliposomes contenant des proteines membranaires a l'aide d'un systeme de synthese proteique acellulaire
WO2009097587A2 (fr) * 2008-01-30 2009-08-06 The Rockefeller University Bicouches liées nanométriques, procédés d'utilisation et production

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEVY D ET AL: "Reconstitution of the sarcoplasmic reticulum Ca<2+>-ATPase: mechanisms of membrane protein insertion into liposomes during reconstitution procedures involving the use of detergents", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 1107, no. 2, 30 June 1992 (1992-06-30), pages 283 - 298, XP027464334, ISSN: 0005-2736, [retrieved on 19920630], DOI: 10.1016/0005-2736(92)90415-I *
SANTOS H D L ET AL: "Na,K-ATPase reconstituted in liposomes: effects of lipid composition on hydrolytic activity and enzyme orientation", COLLOIDS AND SURFACES. B, BIOINTERFACES, ELSEVIER, AMSTERDAM, NL, vol. 41, no. 4, 10 April 2005 (2005-04-10), pages 239 - 248, XP027803517, ISSN: 0927-7765, [retrieved on 20050410] *
SEDDON A M ET AL: "Membrane proteins, lipids and detergents: not just a soap opera", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 1666, no. 1-2, 3 November 2004 (2004-11-03), pages 105 - 117, XP004617558, ISSN: 0005-2736, DOI: 10.1016/J.BBAMEM.2004.04.011 *
See also references of EP2611419A2 *

Also Published As

Publication number Publication date
KR20130047749A (ko) 2013-05-08
EP2611419A2 (fr) 2013-07-10
JP2013544488A (ja) 2013-12-19
MX2013001541A (es) 2013-03-18
WO2012028524A2 (fr) 2012-03-08
RU2013111678A (ru) 2014-10-10
CA2807433A1 (fr) 2012-03-08
BR112013004397A2 (pt) 2017-06-27
CN103068368A (zh) 2013-04-24

Similar Documents

Publication Publication Date Title
WO2012028524A3 (fr) Procédé de production d&#39;une particule lipidique, particule lipidique elle-même et son utilisation
WO2012123014A3 (fr) Système limiteur de courant conçu pour limiter les effets d&#39;une défaillance dans une grille à courant continu et procédé pour faire fonctionner un système limiteur de courant
WO2013158182A3 (fr) Procédé de fabrication de panneau sandwich
WO2011153246A3 (fr) Extraction d&#39;un lipide à partir de cellules et produits obtenus à partir de cette extraction
EP2663450A1 (fr) Structures stratifiées composites et procédés de fabrication et d&#39;utilisation associés
WO2014201362A3 (fr) Traitement d&#39;applications de vision artificielle
ZA201109191B (en) Mehtod for manufacturing composite connecting rods,and connecting rods produced according to the method
WO2011000879A3 (fr) Procédé de production d&#39;un produit laitier fermenté
WO2015028324A3 (fr) Procédé de production de resvératrol modifié
WO2012142007A3 (fr) Composants de chambre texturés à durée de vie allongée, et procédé de fabrication de ces composants
WO2012134086A3 (fr) Squelette tridimensionnel de nanofibres pour réparation tissulaire et son procédé de préparation
WO2013003297A3 (fr) Module de noyau de stator, ensemble de noyau de stator et procédé pour assembler un ensemble de noyau de stator
WO2011031849A3 (fr) Lipides anioniques et nanostructures lipidiques et leurs procédés de fabrication et d&#39;utilisation
EP2676172A4 (fr) Système à lasers ircm à semi-conducteurs, à génération directe
WO2012085286A3 (fr) Élément photovoltaïque
EP2682242A4 (fr) Planche en bambou et planche composite et leur procédé de fabrication
WO2013106112A3 (fr) Panneau comportant une couche de cœur et procédé
WO2012114122A3 (fr) Panneau de construction
EP2433778A3 (fr) Procédé de réduction de rétrécissement différentiel dans stéréolithographie
WO2013084160A3 (fr) Composite de graphène et procédé de fabrication d&#39;un composite de graphène
WO2013092920A3 (fr) Procede de realisation d&#39;un resonateur
WO2011034551A3 (fr) Préparations pharmaceutiques à base de 9-cis-retinyl esters dans un véhicule lipidique
WO2013025161A3 (fr) Système et procédé pour des étiquettes mobiles possédant un contenu dynamique
WO2012034053A3 (fr) Augmentation de la concentration des terpènes dans les liquides
WO2011156212A3 (fr) Procédé pour la dégradation des boues provenant de pâte à papier et de fabrication de papier

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180038671.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11749404

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2011749404

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011749404

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2807433

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/001541

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013526413

Country of ref document: JP

Kind code of ref document: A

Ref document number: 20137005032

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013111678

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013004397

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013004397

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130225